Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1721-1726

  Zhou, Xiao Jian ^a   Marbury, Thomas C ^b   Alcorn, Harry W ^c   Smith, William B ^d   Patrick, Gloria Dubuc ^a   Chao, George C ^a   Brown, Nathaniel A ^a  

^a Idenix Pharmaceuticals Inc   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c DAVITA CLINICAL RESEARCH   (United States)

^d New Orleans Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NUCLEOSIDE DERIVATIVE; TELBIVUDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATITIS B; HUMAN; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; PRURITUS; SCORING SYSTEM; SINGLE DRUG DOSE; TIME; TIME TO REACH MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; AREA UNDER CURVE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LIVER DISEASES; MALE; MASS SPECTROMETRY; MIDDLE AGED; NUCLEOSIDES; PYRIMIDINONES; SEVERITY OF ILLNESS INDEX;

EID: 33646445007     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1721-1726.2006     Document Type: Article

References (20)

1. Bifano, M., J. H. Yan, J. Xie, D. Zhang, J. Freund, S. Rahim, G. Hanna, F. La Creta, and D. Grasela. 2004. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir. Hepatology 40(Suppl. 1):663A.
2. Bryant, M. L., E. G. Bridges, L. Placidi, A. Faraj, A.-G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J.-L. Imbach, B. Hernandez, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, P. Marion, E. Cretton-Scott, R. F. Schinazi, and J.-P. Sommadossi. 2001. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45:229-235.
3. Fournier, A., and J. M. Achard. 2000. Mnemotechnical note on the use of Cockcroft creatinine clearance formula for the validation of a 24-h urine collection. Nephrol. Dial. Transplant. 15:1677-1678.
4. Ginès, P., and P. Sort. 1998. Pathophysiology of renal dysfunction in cirrhosis. Digestion 59(Suppl. 2):11-15.
5. Hernandez-Santiago, B., L. Placidi, E. Cretton-Scott, A. Faraj, E. G. Bridges, M. L. Bryant, J. Rodriguez-Orengo, J. L. Imbach, G. Gosselin, C. Pierra, D. Dukhan, and J. P. Sommadossi. 2002. Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. 46:1728-1733.
6. Johnson, M. A., J. Horak, and P. Breuel. 1998. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur. J. Clin. Pharmacol. 54:363-366.
7. Kearney, B. P., Y. Benharaoul, J. Flaherty, J. Sayre, K. Yale, G. Currie, J. Shah, and A. Cheng. 2004. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis, abstr. 600. 11th Conference on Retroviruses and Opportunistic Infections.
8. Knight, W., S. Hayashi, Y. Benhamou, G. Currie, R. Ebrahimi, S. Gill, J. Fry, B. Kearney, and C. Brosgart. 2002. Dosing guidelines for adefovir dipivoxil in the treatment of chronic hepatitis B patients with renal or hepatic impairment. J. Hepatol. 36(Suppl. 1):136.
9. Lai, C.-L., N. W. Y. Leung, E.-K. Teo, M. Tong, F. Wong, H.-W. Hann, S. Han, T. Poynard, M. Myers, G. Chao, D. Lloyd, and N. Brown, Telbivudine Phase II Investigator Group. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536.
10. Lai, C.-L., S. G. Lim, N. A. Brown, X.-J. Zhou, D. M. Lloyd, Y.-M. Lee, M.-F. Yuen, G. C. Chao, and M. W. Myers. 2004. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40:719-726.
11. Salazar, D. E., and G. B. Corcoran. 1988. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am. J. Med. 84:1053-1060.
12. Schaad, H. J., B. G. Petty, D. M. Grasela, B. Christofalo, R. Raymond, and M. Stewart. 1997. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment. Antimicrob. Agents Chemother. 41:2793-2796.
13. Seifer, M., A. Patty, D. Dukhan, G. Gosselin, J. L Imbach, J. P. Sommadossi, M. Bryant, and D. Standring. 2005. Telbivudine (LdT) preferentially inhibits second (+) strand HBV DNA synthesis. J. Hepatol. 42(Suppl. 2):151.
14. Sherman, D. S., D. N. Fish, and I. Teitelbaum. 2003. Assessing renal function in cirrhotic patients: problems and pitfalls. Am. J. Kidney Dis. 41:269-278.
15. Verbeeck, R. K., and Y. Horsmans. 1998. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm. World Sci. 20:183-192.
16. Zhou, X. J., B. Fielman, D. Lloyd, G. Chao, and N. Brown. 2005. Absence of pharmacokinetic drug-drug interaction between telbivudine and lamivudine or adefovir in healthy subjects. J. Hepatol. 42(Suppl. 2):197.
17. Zhou, X. J., S. G. Lim, C. L. Lai, P. F. Lam, D. M. Pow, N. A. Brown, and M. W. Myers. 2001. Pharmacokinetics of β-L-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection, p. 92, abstr. 100. Frontiers in Drug Development for Viral Hepatitis.
18. Zhou, X. J., S. G. Lim, D. M. Lloyd, G. C. Chao, N. A. Brown, and C. L. Lai. 2006. Pharmacokineties of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob. Agents Chemother. 50:874-879.
19. Zhou, X. J., D. M. Lloyd, C. C. Chao, and N. A. Brown. 2006. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J. Clin. Pharmacol. 46:275-281.
20. Zhou, X. J., M. Myers, G. Chao, G. Dubuc, and N. A. Brown. 2004. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function. Hepatology 40(Suppl. 1):672A.